Danahy Kevin Patrick
Known title: Chief Executive OfficerCIK: 0001913245
Danahy Kevin Patrick's purchase track record
Danahy Kevin Patrick has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/16/2023 | PLSE | $35K | +47.4% | +26.4% | +17.5% |
| 9/30/2022 | PLSE | $15K | +20.4% | +46.1% | +14.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PLSE | ▲ Buy | Option Exercise | 5,000 | $8K | 2/18/2026 | View on chart |
| PLSE | ▼ Sell | Open Market | 5,000 | $118K | 2/18/2026 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $31K | 2/17/2026 | View on chart |
| PLSE | ▼ Sell | Open Market | 20,000 | $473K | 2/17/2026 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $31K | 2/13/2026 | View on chart |
| PLSE | ▼ Sell | Open Market | 20,000 | $471K | 2/13/2026 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $31K | 2/12/2026 | View on chart |
| PLSE | ▼ Sell | Open Market | 20,000 | $467K | 2/12/2026 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $31K | 2/11/2026 | View on chart |
| PLSE | ▼ Sell | Open Market | 20,000 | $504K | 2/11/2026 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $31K | 2/10/2026 | View on chart |
| PLSE | ▼ Sell | Open Market | 20,000 | $470K | 2/10/2026 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $31K | 2/9/2026 | View on chart |
| PLSE | ▼ Sell | Open Market | 20,000 | $429K | 2/9/2026 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 4,600 | $7K | 10/2/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 4,600 | $85K | 10/2/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 400 | $7K | 9/19/2025 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 400 | $612 | 9/19/2025 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $31K | 9/18/2025 | View on chart |
| PLSE | ▼ Sell | Open Market | 20,000 | $370K | 9/18/2025 | View on chart |
| PLSE | ▼ Sell | Other | 650 | — | 7/3/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 4,781 | $31K | 11/16/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 600 | $4K | 11/16/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 12 | $78 | 11/16/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 6,500 | $15K | 9/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pulse Biosciences Partners with Clayman Thyroid Center
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.
Pulse Biosciences Partners with Clayman Thyroid Center. Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.